Why CROs Lose Bids They Should Win

A sponsor RFP lands in your inbox on a Tuesday. You have ten days.

You call the strategy meeting. You pull pre-award feasibility on the line. You chase every internal function for their numbers. You ship the proposal on day nine with every box ticked, every appendix attached, every functional sign-off collected. You feel good. You did the work.

Five weeks later, you find out you lost to a competitor who did exactly what you did, in exactly the same order, with exactly the same diligence, and quoted a lower price.

Of course you did. You and your five competitors were running the same race, on the same track, against the same clock. The sponsor watched you all cross the finish line, picked the cheapest, and moved on.

This happens every single time. It will keep happening until you stop running the race.

A few weeks ago I wrote about why pharma and biotech sponsors have a hard time choosing the right CRO. Today I want to focus on the other side: how CROs hand themselves over to the price war, on the sponsor’s terms, on the sponsor’s frame, before bid defence even starts.

The research

I analyzed the top 50 CROs globally: investor calls where available, headcount curves, hiring velocity, anything I could pull to see who was actually growing and who was on the slow slide down. I reached out to the chief commercial officers at a dozen of them, and to the BD directors where the CCOs gave no answer, and asked why their organization grew while peers shrunk, or shrunk while peers grew.

On top of that I read 17 proposals. Five from two of the top-five CROs for large interventional Phase III trials, and a dozen from midsize CROs (1,500+ FTE) across single-site through 10-country studies, simple indications through oncology, respiratory, obesity, CNS, and rare disease.

Three of the 17 demonstrated any consultative reframing at all. The other 14 were technical worksheets in different fonts.

I want to thank everyone who shared their data. Much of this research feeds how we are building Yendou, but the conclusions are useful even if you never touch our product. What I am about to share will help you build better commercial operations, win more deals, and deliver more revenue.

Here is the single biggest mistake I saw across nearly every proposal:

The assumption is that the sponsor wants answers to the questions in the RFP. The sponsor does not want answers to the questions in the RFP.

What the sponsor actually wants

The sponsor wants the asset to succeed. There is enormous pressure on the asset, on the patient strategy, on the protocol design, and on every operational decision downstream of all of it. Failure is not a possibility the sponsor is allowed to contemplate. Their job, their board’s patience, and the next round of funding are all attached to this molecule.

The sponsor is not shopping for vendor data. The sponsor is shopping for a success roadmap.

What they want cannot be fit into a worksheet. They want to know whether your team is trustworthy to have in the room when operational reality starts deviating from the hypothetical delivery timeline. They want to know whether you can see what they cannot. They want to know whether the timeline in the RFP is actually achievable, and if not, whether you are honest enough to say so.

Underneath every question in the document is one psychological driver: can I trust your team with the asset my career is attached to?

Your commercial process is not built to surface any of that. It is built to deliver completed answers, on time. The KPI is response completeness. The reward is shipping on day nine with all boxes ticked. You are optimizing for the wrong thing.

And it is not just you. Every other CRO competing for this bid is optimizing for the same wrong thing. Most CRO proposals are inert as instruments of persuasion. They are an accumulation of raw, dry technical information being handed to a buyer who is looking for operational judgment. The whole industry has converged on the same race, and the only variable left to compete on is price.

This is the Anti-Differentiation Trap. The RFP is structurally designed to make every CRO look identical to every other CRO. By answering it literally, you accept the sponsor’s frame of comparability and dissolve everything that makes your organization unique. The moment a buyer can compare you cleanly, price becomes the only variable left.

Why CROs do not see it

I will concede the one thing worth conceding here. There are real reasons CROs operate this way, and the explanation is not laziness.

Completeness feels like virtue. The proposal team can measure it. Every question answered, every appendix attached, every signature collected. It is satisfying work. It feels like competence. And it sells internally: when the head of pre-award sits in a leadership review, there is a clean metric to put on the dashboard. Bids shipped per quarter is what gets a pre-award team budget for the next one.

Time pressure plays a role too. Asking the team to think strategically while the scope of manual work exceeds the hours in the day is like asking the line cook to redesign the menu mid-service. The body cannot sprint and think at the same time.

One of the CCOs I spoke to put it directly. He had been running pre-award for over two decades. I asked how many of his last hundred bids his team had won. He shrugged. About fourteen. I asked how many of those fourteen he could have predicted, going in. He thought for a moment. Probably all fourteen, he said. How did he know?

That conversation is the entire problem in three answers.

But here is the question almost nobody asks: why do those 10 days feel impossible in the first place?

Walk through the standard RFP processing timeline and you will see what is actually going on.

The 10-day bottleneck and the fallacy of “special” budgets

The traditional pre-award process is a people pipeline, not a data pipeline. When a complex protocol lands with a compressed turnaround, the operational clock begins to bleed immediately.

The standard, broken timeline looks like this:

• Day 1–2. Internal alignment calls and manual reading of provided material.
• Day 3–5. The commercial team chases internal functions to get the capabilities questionnaire filled.
• Day 3–8. Pre-award feasibility chasing sites for insights to support a defensible allocation strategy. An overworked proposal team chasing overworked department heads, debating line items and people-and-time investment per service. Everyone still waiting for feasibility data. Everyone operating under the assumption that their specific department’s budget is a special snowflake requiring custom, manual calculations.
• Day 9–10. A proposal manager frantically copy-pastes numbers into a massive, macro-heavy master spreadsheet, and delivers a technical document at the final hour.

So what does the CRO actually ship at the end of all that?

A clean, dry, complete proposal that looks exactly like the four others sitting on the sponsor’s desk.

The reason the timeline feels impossible is not that 10 days is too short. The reason is that CROs treat every proposal as a novel mathematical emergency built row by row from scratch, and so they burn the team’s sharpest intellectual energy on basic data entry and spreadsheet navigation. The strategic work that would have changed the outcome of the bid never gets started, because nobody has the cognitive room to start it.

After decades of industry data and thousands of historical bids, you have already priced virtually every complexity level that exists. The combination of therapeutic area, phase, study design, and region produces highly predictable patterns. The baseline cost is a lookup. Turning that raw data into sponsor confidence is the real commercial job, and it is the job that almost never gets done.

This is the question I keep coming back to. When are you going to turn your fifteen years of historical bids into the engine that collapses the 10-day race into a 48-hour calculation?

If you are already asking yourself the same question, we should compare notes. I am running a closed co-design forum for CRO commercial leaders who are building the proposal engine the industry should have built years ago.

The trap of technical jargon vs. consultative framing

There is a second trap that runs alongside the first. It is the trap of language.

This is the one the 14 proposals fell into. When the sponsor asks a CRO to describe its team expertise, its enrollment strategy, or its monitoring approach, the weak proposal reaches for boilerplate: multi-decade, robust, proven, deep therapeutic expertise, site-focused, patient-centric, purpose-built. It is identical to every other vendor on the shortlist. It accepts the sponsor’s exact frame and joins the pile. And when you look exactly like your competitors, the only thing left for the sponsor to act on is price.

A winning proposal changes the category of the conversation. It uses a consultative frame to reframe the problem and to tell the sponsor what should actually be keeping them up at night.

Capabilities are the cost of entry, not the reason to win. Therapeutic credentials, investigator network size, ISO certifications, clean SOPs: these earn you the right to be read. They do not earn you the right to be chosen.

A biotech sponsor does not send out a complex protocol because they are shopping for vendor data. They send it because they are sitting on an extremely volatile asset that the next funding round, the investors’ patience, and the team’s own career are all tied to. You win the bid by demonstrating that you understand what the sponsor is holding, better than they do.

When the RFP asks for an enrollment plan, the commodity response details your generic processes (copy-pasted from the last one). The consultative response does something else entirely:

You did not answer the sponsor’s question. You corrected it. In correcting it, you made every other proposal in the pile feel administrative. You moved the conversation off price, onto trust, which is the only ground you can actually win on.

There is one caveat for anyone tempted by the move and not the discipline behind it. The consultative reframe only works if you actually have the data. CROs that bluff this get caught instantly on bid defence. The reframe is downstream of structured institutional memory; without that, it is just confident copy.

The structural fix: decouple pricing from validation

The reason most CROs cannot operate this way is structural. The pre-award engine tries to solve two completely different problems in the same compressed window.

Trial pricing is fast. It is a lookup against historical bid libraries, role-specific rate cards, and complexity tiers. With clean institutional memory, you can generate, review, and approve it in 24 to 48 hours from document receipt. It requires no external outreach.

Delivery validation is slow. It is real-world feasibility, investigator landscaping, site qualification, local CDA negotiation, and investigator-led compound and protocol insights. It runs on human cycles and email ping-pong, and it does not get faster by yelling at it.

When you serialize these two activities, with pricing waiting for site and function validation, or worse, with validation gating pricing, the slow loop holds the fast loop hostage. A 10-minute calculation waits behind three weeks of email. By the time the proposal ships, the team’s scarce strategic attention has been spent on a deadline, not on the consultative reframe that would have won the bid.

The fix is to decouple them. Ship the proposal at the velocity of pricing, with consultative reframing baked in. Shipping pricing early also buys the BD team something invisible but enormous: room to gather more insights into the sponsor’s core intent and constraints, which then informs validation work and produces scenarios that are genuinely useful to the sponsor instead of generic.

Run validation in parallel, asynchronously, while the sponsor evaluates. By the time the buying committee shortlists you, your operational verification has caught up. You arrive with both speed and depth. Your competitors arrive with neither.

The discipline almost nobody practices: choosing not to bid

Most CROs measure pre-award productivity by proposals shipped. This is hollow.

Procurement teams routinely pull mid-market CROs into long-list RFPs for one reason: to create price tension against an incumbent who already won the deal eighteen months ago, in a series of dinners and advisory boards you were not invited to. You are not bidding. You are the wall the incumbent’s price bounces off so it sounds reasonable to procurement.

The cost of preparing a serious proposal is enormous, and the strategic value of preparing one for a bid you cannot win is zero. Every hour the team spends on these is an hour the team did not spend on the bid it could have won.

A disciplined commercial operation gates every RFP against three questions before a single cell of a financial model is touched.

1. Have we moved past the procurement portal to an actual strategic dialogue with the clinical decision-maker?
2. Can we identify a named internal champion advocating for our methodology?
3. Do we have a documented asymmetric advantage (site activation track record, regional network, indication-specific operations) that gives us a demonstrably safer path than the incumbent?

If the answer to any of these is no, the bid declines itself. Step out of the race. Redirect your scarce strategic attention toward the accounts you can actually win.

What I am not saying

I should name what this piece is not.

My sample is biased. 17 proposals is a small N, and the CCOs who agreed to talk to me are probably the ones who already suspected something was wrong with their process. My data is also weighted toward midsize CROs (1,500+ FTE) and toward Phase II/III oncology, where I have spent most of my career. If your data contradicts mine, I want to see it.

I am also not saying every CRO can rebuild their pre-award engine tomorrow. Many of them do not have structured bid data. The historical proposals exist as PDFs in inboxes, not as a queryable library. Building the engine I am describing requires building the institutional memory first, and most CROs do not have the time for that. I know. Frankly, this should be your priority.

And finally, I am not putting this all on CROs. The procurement instrument that produces these proposals is broken on the sponsor side too. The RFP is a form sponsors inherited and have not redesigned in a generation. The most successful sponsor-CRO relationships I have seen are the ones where both sides have agreed, quietly, to do the real work outside the form. The form is the “standard procedure”. The conversation is the deal.

What I am saying is that the trap is real, the cost is enormous, and the CROs that solve it will grow. Meaningfully.

The verdict

Looking at all these proposals, here is what I see. CRO pre-award activity often feels like a race against the clock to ship a complete document. But completeness is not persuasion. Completeness tells the sponsor what your organization has. Persuasion tells the sponsor what your team will do on this specific protocol, under real constraints, when the plan starts to break.

CROs do not need faster proposal teams. They need a different commercial instrument. They need to be able to price quickly enough to spend the rest of the window thinking, to reframe the protocol back to the sponsor in ways that demonstrate operational judgment, and to walk away from the bids that were never theirs to win.

As a CRO, what you are selling is not a proposal document. That is the artifact. What you are selling is the certainty that the asset on the other side will reach its readout. The sponsor wants to get to an answer: can I trust this team to ship my trial on time, on budget, and to a quality bar I can defend?

What you are selling is the team that can deliver that answer.